SELLAS Life Sciences (SLS) Net Income (2010 - 2026)
SELLAS Life Sciences (SLS) reported Net Income of -$8.4 million for Q1 2026, down 44.62% year-over-year from -$15.2 million in Q1 2025, and down 9.78% on a QoQ basis from -$7.7 million in Q4 2025.
SELLAS Life Sciences (SLS) has 15 years of Net Income data on file, last reported at -$8.4 million in Q1 2026.
- Quarterly Net Income fell 44.62% year-over-year to -$8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.5 million (down 8.59% YoY) and the FY2025 annual result came in at -$26.9 million, up 13.01% from the prior year.
- Net Income fell to -$8.4 million in Q1 2026 per SLS's latest filing, from -$7.7 million in the prior quarter.
- Across five years, Net Income topped out at -$5.8 million in Q1 2025 and bottomed at -$16.7 million in Q1 2022.
- The 5-year median for Net Income is -$8.1 million (2023), against an average of -$8.6 million.
- The widest annual swing landed in 2022, when Net Income sank 645.43%; it then soared 39.23% in 2025.
- Tracing SLS's Net Income over 5 years: stood at -$9.4 million in 2022, then gained by 13.87% to -$8.1 million in 2023, then advanced by 17.2% to -$6.7 million in 2024, then slipped by 13.67% to -$7.7 million in 2025, then declined by 9.78% to -$8.4 million in 2026.
- Per Business Quant, the three latest SLS Net Income figures stand at -$8.4 million (Q1 2026), -$7.7 million (Q4 2025), and -$6.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | -8.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.41 Mn |
| Dec 31, 2025 | -7.66 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -5.81 Mn |
| Dec 31, 2024 | -6.74 Mn |
| Sep 30, 2024 | -7.11 Mn |
| Jun 30, 2024 | -7.47 Mn |
| Mar 31, 2024 | -9.57 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Sep 30, 2023 | -9.27 Mn |
| Jun 30, 2023 | -8.84 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | -6.98 Mn |
| Jun 30, 2021 | -4.45 Mn |
| Mar 31, 2021 | -2.25 Mn |
| Dec 31, 2020 | -4.16 Mn |
| Sep 30, 2020 | -4.49 Mn |
| Jun 30, 2020 | -4.27 Mn |
| Mar 31, 2020 | -4.06 Mn |
| Dec 31, 2017 | -8.65 Mn |
| Sep 30, 2017 | 118,000.00 |
| Jun 30, 2017 | -1.30 Mn |
| Mar 31, 2017 | -9.44 Mn |
| Dec 31, 2016 | -3.58 Mn |
| Sep 30, 2016 | -2.59 Mn |
| Jun 30, 2016 | -2.89 Mn |
| Mar 31, 2016 | -3.39 Mn |
| Dec 31, 2015 | -8.87 Mn |
| Sep 30, 2015 | -11.67 Mn |
| Jun 30, 2015 | -2.19 Mn |
| Mar 31, 2015 | -2.23 Mn |
| Dec 31, 2014 | 14.96 Mn |
| Sep 30, 2014 | -2.64 Mn |
| Jun 30, 2014 | -16.27 Mn |
| Mar 31, 2014 | -11.85 Mn |
| Dec 31, 2013 | 5.35 Mn |
| Jun 30, 2013 | -9.60 Mn |
| Mar 31, 2013 | -9.29 Mn |
| Jun 30, 2012 | -423,000.00 |
| Mar 31, 2012 | -1.22 Mn |
| Dec 31, 2011 | -2.18 Mn |
| Sep 30, 2011 | -1.64 Mn |
| Jun 30, 2011 | -2.16 Mn |
| Jun 30, 2010 | -4.75 Mn |